zasocitinib
Aug 17, 2026
TYK2 Inhibitors: The Competitive Race Fueling the Next Generation of Autoimmune Therapies
Summary TYK2 inhibitors are emerging as a major class of oral immunology therapies, aiming to combine biologic-level efficacy with the convenience of a pill and fewer safety concerns than broader JAK inhibitors. Bristol Myers Squibb’s SOTYKTU remains the first approved TYK2 inhibitor and expanded its positio...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
